Candesartan in the treatment of hypertension: what have we learnt in the last decade?

Bibliography

• Dzau VJ, Bernstein K, Celermajer D, Pathophysiologic and therapeutic importance of tissue ACE: a consensus report. Cardiovasc Drugs Ther 2002;10:149-60
   Web of Science ®Google Scholar
• Barrios V, Escobar C, Calderon A. Candesartan: from left ventricular hypertrophy to heart failure, a global approach. Expert Rev Cardiovasc Ther 2007;5:825-34
   PubMedGoogle Scholar
• Goodfriend TL, Elliott ME, Catt KJ. Angiotensin receptors and their antagonists. N Engl J Med 1996;334:1649-54
   PubMed Web of Science ®Google Scholar
• Ford WR, Clanachan AS, Jugdutt BI. Opposite effects of angiotensin AT1 and AT2 receptor antagonists on recovery of mechanical function after ischemia-reperfusion in isolated working rat hearts. Circulation 1996;94:3087-9
   PubMed Web of Science ®Google Scholar
• Griendling KK, Lassegue B, Alexander RW. Angiotensin receptors and their therapeutic implications. Annu Rev Pharmacol Toxicol 1996;36:281-306
   PubMed Web of Science ®Google Scholar
• Server P. Candesartan cilextil: a new, long-acting, effective angiotensin II Type 1 receptor blocker. J Hum Hypertens 1997;1(Suppl 2):S91-5
   Google Scholar
• Nishikawa K, Naka T, Chatani F, Yoshimura Y. Candesartan cilexetil: a review of its preclinical pharmacology. J Hum Hypertens 1997;11(Suppl 2):S9-17
   PubMed Web of Science ®Google Scholar
• van Lier JJ, van Heiningen PNM, Sunzel M. Absorption metabolism and excretion of candesartan and candesartan cilexetil in healthy volunteers. J Hum Hypertens 1997;11(Suppl 2):S27-8
   PubMed Web of Science ®Google Scholar
• Malmqvist K, Kahan T, Dahl M. Angiotensin II type 1 (AT1) receptor blockade in hypertensive women: benefits of candesartan cilexetil versus enalapril or hydrochlorothiazide. Am J Hypertens 2000;13:504-11
   PubMed Web of Science ®Google Scholar
• Nixon RM, Muller E, Lowy A, Falvey H. Valsartan vs. other angiotensin II receptor blockers in the treatment of hypertension: a meta-analytical approach. Int J Clin Pract 2009;63:766-75
   PubMed Web of Science ®Google Scholar
• Derosa G, Maffioli P, Salvadeo SA, Differential effects of candesartan and olmesartan on adipose tissue activity biomarkers in type II diabetic hypertensive patients. Hypertens Res 2010;33:790-5
   PubMed Web of Science ®Google Scholar
• Himmelmann A, Keinanen-Kiukaanniemi S, Wester A, The effect duration of candesartan cilexetil once daily, in comparison with enalapril once daily, in patients with mild to moderate hypertension. Blood Press 2001;10:43-51
   PubMed Web of Science ®Google Scholar
• Bakris G, Gradman A, Reif M, Antihypertensive efficacy of candesartan in comparison to losartan: the CLAIM study. J Clin Hypertens 2001;3:16-21
   PubMedGoogle Scholar
• Vidt DG, White WB, Ridley E, CLAIM Study Investigators. A forced titration study of antihypertensive efficacy of candesartan cilexetil in comparison to losartan: CLAIM Study II. J Hum Hypertens 2001;15:475-80
   PubMed Web of Science ®Google Scholar
• Lacourciere Y, Asmar R. A comparison of the efficacy and duration of action of candesartan cilexetil and losartan as assessed by clinic and ambulatory blood pressure after a missed dose, in truly hypertensive patients: a placebo-controlled, forced titration study. Candesartan/Losartan study investigators. Am J Hypertens 1999;12:1181-7
   PubMed Web of Science ®Google Scholar
• Zheng Z, Shi H, Jia J, A systematic review and meta-analysis of candesartan and losartan in the management of essential hypertension. J Renin Angiotensin Aldosterone Syst 2011; published online 18 March 2011; DOI: 10.1177/1470320310391503
   Web of Science ®Google Scholar
• Julius S, Nesbitt SD, Egan BM, Feasibility of Treating Prehypertension with an Angiotensin-Receptor Blocker. N Engl J Med 2006;354:1685-97
   PubMed Web of Science ®Google Scholar
• Lithell H, Hansson L, Skoog I, The Study on Cognition and Prognosis in the Elderly (SCOPE): principal results of a randomized double-blind intervention trial. J Hypertens 2003;21:875-86
   PubMed Web of Science ®Google Scholar
• Papademetriou V, Farsang C, Elmfeldt D, Stroke prevention with the angiotensin II type 1-receptor blocker candesartan in elderly patients with isolated systolic hypertension: the Study on Cognition and Prognosis in the Elderly (SCOPE). J Am Coll Cardiol 2004;44:1175-80
   PubMed Web of Science ®Google Scholar
• Trachtman H, Hainer JW, Sugg J, Candesartan in Children with Hypertension (CINCH) Investigators. Efficacy, safety, and pharmacokinetics of candesartan cilexetil in hypertensive children aged 6 to 17 years. J Clin Hypertens (Greenwich) 2008;10:743-50
   PubMed Web of Science ®Google Scholar
• Schaefer F, van de Walle J, Zurowska A, Efficacy, safety and pharmacokinetics of candesartan cilexetil in hypertensive children from 1 to less than 6 years of age. J Hypertens 2010;28:1083-90
   PubMed Web of Science ®Google Scholar
• Barrios V, Escobar C, Calderon A, Cardiovascular risk profile and risk stratification of the hypertensive population attended by general practitioners and specialists in Spain. The CONTROLRISK study. J Hum Hypertens 2007;21:479-85
   PubMed Web of Science ®Google Scholar
• Mancia G, De Backer G, Dominiczak A, 2007 Guidelines for the management of arterial hypertension: the task force for the management of arterial hypertension of the european society of hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens 2007;25:1105-87
   PubMed Web of Science ®Google Scholar
• Levy D, Garrison RJ, Savage DD, Prognostic implications of echocardiographically determined left ventricular mass in the Framingham Heart Study. N Engl J Med 1990;322:1561-6
   PubMed Web of Science ®Google Scholar
• Verdecchia P, Angeli F, Borgioni C, Changes in cardiovascular risk by reduction of left ventricular mass in hypertension: a meta-analysis. Am J Hypertens 2003;16:895-9
   PubMed Web of Science ®Google Scholar
• Mathew J, Sleight P, Lonn E, Reduction of cardiovascular risk by regression of electrocardiographic markers of left ventricular hypertrophy by the angiotensin-converting enzyme inhibitor ramipril. Circulation 2001;104:1615-21
   PubMed Web of Science ®Google Scholar
• Cuspidi C, Muiesan ML, Valagussa L, Comparative effects of candesartan and enalapril on left ventricular hypertrophy in patients with essential hypertension: the candesartan assessment in the treatment of cardiac hypertrophy (CATCH) study. J Hypertens 2002;20:2293-300
   PubMed Web of Science ®Google Scholar
• Barrios V, Escobar C, Calderon A, Regression of left ventricular hypertrophy by a candesartan-based regimen in clinical practice. The VIPE Study. J Renin Angiotensin Aldosterone Syst 2006;7:236-42
   PubMed Web of Science ®Google Scholar
• Barrios V, Calderon A, Escobar C, Electrocardiographic left ventricular hypertrophy by an angiotensin receptor blocker-based regimen in daily clinical practice. The SARA study. J Hypertens 2007;25:1967-73
   PubMed Web of Science ®Google Scholar
• Barrios V, Escobar C, Calderon A. Cardiovascular protection with candesartan in patients with metabolic disorders. Hypertens Res 2010;33:1312-13
   PubMed Web of Science ®Google Scholar
• Barrios V, Escobar C, Calderon A, Gender differences in the diagnosis and treatment of left ventricular hypertrophy detected by different electrocardiographic criteria. Findings from the SARA study. Heart Vessels 2010;25:51-6
   PubMed Web of Science ®Google Scholar
• Barrios V, Escobar C, Calderon A, Electrocardiographic left ventricular hypertrophy regression induced by an angiotensin receptor blocker-based regimen in hypertensive patients with diabetes: data from the SARA study. J Renin Angiotensin Aldosterone Syst 2009;10:168-73
   PubMed Web of Science ®Google Scholar
• Escobar C, Barrios V, Calderon A, Electrocardiographic left ventricular hypertrophy regression induced by an angiotensin receptor blocker-based regimen in hypertensive patients with the metabolic syndrome: data from the SARA Study. J Clin Hypertens (Greenwich) 2008;10:208-14
   PubMed Web of Science ®Google Scholar
• Barrios V, Escobar C, Calderon A, Regression of left ventricular hypertrophy in diabetics by a candesartan-based regimen in clinical practice. Diabetes Res Clin Pract 2007;77:492-3
   PubMed Web of Science ®Google Scholar
• Mogensen CE, Neldam S, Tikkanen I, for the CALM study group. Randomised controlled trial of dual blockade of renin­angiotensin system in patients with hypertension, microalbuminuria, and non­insulin dependent diabetes: the candesartan and lisinopril microalbuminuria (CALM) study. BMJ 2000;321:1440-4
   PubMed Web of Science ®Google Scholar
• Bilous R, Chaturvedi N, Sjølie AK, Effect of candesartan on microalbuminuria and albumin excretion rate in diabetes: three randomized trials. Ann Intern Med 2009;151:11-20
   PubMed Web of Science ®Google Scholar
• Karlson BW, Zetterstrand S, Olofsson B, Elmfeldt D. A dose-response analysis of candesartan-hydrochlorothiazide combination therapy in patients with hypertension. Blood Press 2009;18:149-56
   PubMed Web of Science ®Google Scholar
• Edes I, Burgess L, Parow W, Combination therapy with candesartan cilexetil 32 mg and hydrochlorothiazide 25 mg provides the full additive antihypertensive effect of the components: a randomized, double-blind, parallel-group study in primary care. Clin Drug Investig 2009;29:293-304
   PubMed Web of Science ®Google Scholar
• Bonner G, Calder B, Dzyak G, Antihypertensive efficacy and tolerability of candesartan-hydrochlorothiazide 32/12.5 mg and 32/25 mg in patients not optimally controlled with candesartan monotherapy. Blood Press Suppl 2008;2:22-30
   PubMedGoogle Scholar
• Ho PM, Magid DJ, Shetterly SM, Importance of therapy intensification and medication nonadherence for blood pressure control in patients with coronary disease. Arch Intern Med 2008;168:271-6
   PubMed Web of Science ®Google Scholar
• Barrios V, Escobar C, Prieto L, Herranz I. Adverse events in clinical trials: is a new approach needed? Lancet 2008;372:535-6
   PubMed Web of Science ®Google Scholar
• Asmar R, Nisse-Durgeat S. A large scale study of angiotensin II inhibition therapy in an elderly population: the CHANCE study. Vasc Health Risk Manag 2006;2:317-23
   PubMedGoogle Scholar
• Motwani JG. Combining renin-angiotensin-aldosterone system blockade with diuretic therapy for treatment of hypertension. J Renin Angiotensin Aldosterone Syst 2002;3:72-8
   PubMed Web of Science ®Google Scholar
• Escobar C, Barrios V. Combined therapy in the treatment of hypertension. Fundam Clin Pharmacol 2010;24:3-8
   PubMed Web of Science ®Google Scholar
• Ketelhut R, Bramlage P. Candesartan cilexetil/hydrochlorothiazide treatment in high-risk patients with type 2 diabetes mellitus and microalbuminuria: the CHILI T2D study. Clin Drug Investig 2010;30:301-11
   PubMed Web of Science ®Google Scholar
• Bonner G, Landers B, Bramlage P. Candesartan cilexetil/hydrochlorothiazide combination treatment versus high-dose candesartan cilexetil monotherapy in patients with mild to moderate cardiovascular risk (CHILI Triple T). Vasc Health Risk Manag 2011;7:81-95
   PubMedGoogle Scholar
• Swedberg K, Pfeffer M, Granger C, Candesartan in heart failure-assessment of reduction in mortality and morbidity (CHARM): rationale and design. J Card Fail 1999;5:276-82
   PubMedGoogle Scholar
• Granger CB, McMurray JJ, Yusuf S, Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting enzyme inhibitors: the CHARM-Alternative trial. Lancet 2003;362:772-6
   PubMed Web of Science ®Google Scholar
• McMurray JJ, Ostergren J, Swedberg K, Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting enzyme inhibitors: the CHARM-Added trial. Lancet 2003;362:767-71
   PubMed Web of Science ®Google Scholar
• Yusuf S, Pfeffer MA, Swedberg K, Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved trial. Lancet 2003;362:777-81
   PubMed Web of Science ®Google Scholar
• Mann JF, Schmieder RE, McQueen M, Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomised, double-blind, controlled trial. Lancet 2008;372:547-53
   PubMed Web of Science ®Google Scholar
• Wang YR, Alexander GC, Stafford RS. Outpatient hypertension treatment, treatment intensification, and control in Western Europe and the United States. Arch Intern Med 2007;167:141-7
   PubMed Web of Science ®Google Scholar
• Barrios V, Banegas JR, Ruilope LM, Rodicio JL. Evolution of blood pressure control in Spain. J Hypertens 2007;25:1975-7
   PubMed Web of Science ®Google Scholar
• Mancia G, Laurent S, Agabiti-Rosei E, Reappraisal of European guidelines on hypertension management: a European Society of Hypertension Task Force document. J Hypertens 2009;27:2121-58
   PubMed Web of Science ®Google Scholar